Source: International Congress 2018 – Biomarkers for evaluating COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Picaud (Lille, France), O. Le Rouzic (Lille, France), H. Salvator (Suresnes, France), H. Neveu (Suresnes, France), P. Devillier (Suresnes, France), L. Couderc (Suresnes, France), T. Perez (Lille, France). Residual reversibility in COPD subjects treated by long acting bronchodilatators. 1068

Member's Comments

No comment yet.

Related content which might interest you: Respiratory muscle strength after inhaled short acting beta-agonist administration in stable COPD patients Source: Annual Congress 2012 - Mechanics, muscles and movement: aspects of airway mechanics, repiratory muscle assessment and field exercise tests Year: 2012 Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 Effects of adding salmeterol to inhaled corticosteroids on lung function and quality of life in patients with mild persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006 Action of long acting β2-agonist and theophylline on circulation parameters in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 404s Year: 2006 Determinants of long acting bronchodilator adherence in UK COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006 The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 240s Year: 2002 Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD Source: Eur Respir J 2016; 47: 651-654 Year: 2016 Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Are inhaled corticosteroids increasing the “load” for some patients with COPD? Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017 Year: 2017 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Acute and chronic effects of inhaled bronchodilators in patients with 'irreversible' COPD at rest and during exercise Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002 Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010 Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001 Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002 The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients Source: Annual Congress 2006 - COPD therapy Year: 2006 Effect of inhaled beta2 agonist on lung compliance in patients with COPD with poor bronchodilator response Source: Eur Respir J 2006; 28: Suppl. 50, 428s Year: 2006 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Effect of dual bronchodilation with indacaterol/glycopirronium on small airways resistance in patients with stable COPD Source: International Congress 2016 – Non-inflammatory COPD monitoring Year: 2016 Which lung function variables are the most sensitive to a short bronchodilator in COPD patients? Source: Annual Congress 2008 - Quality spirometry: the only spirometry! Year: 2008 Withdrawal of inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: who is suitable for a trial of withdrawal? Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019